|
US7666400B2
(en)
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
EP1631496B1
(en)
|
2003-04-28 |
2014-02-26 |
Medical Instill Technologies, Inc. |
Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
|
|
US8435539B2
(en)
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8034352B2
(en)
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US8003111B2
(en)
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8491914B2
(en)
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US8562988B2
(en)
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US9623115B2
(en)
|
2005-04-06 |
2017-04-18 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Disease Therapy
|
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US9222728B2
(en)
|
2006-04-24 |
2015-12-29 |
Medinstill Development Llc |
Penetrable and resealable lyophilization device
|
|
JP5699362B2
(ja)
*
|
2008-04-10 |
2015-04-08 |
アイビーシー ファーマスーティカルズ，インコーポレイテッド |
薬物動態が改善された四量体サイトカインをドック・アンド・ロック（ｄｎｌ）技術により調製するためのモジュール法
|
|
KR20110008086A
(ko)
*
|
2008-04-11 |
2011-01-25 |
메리맥 파마슈티컬즈, 인크. |
인간 혈청 알부민 링커 및 그 콘쥬게이트
|
|
AU2009282830B2
(en)
|
2008-08-20 |
2013-11-28 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) vaccines for cancer therapy
|
|
JP5677972B2
(ja)
*
|
2008-11-18 |
2015-02-25 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ヒト血清アルブミンリンカーおよびそのコンジュゲート
|
|
US20120263701A1
(en)
|
2009-08-24 |
2012-10-18 |
Volker Schellenberger |
Coagulation factor vii compositions and methods of making and using same
|
|
US20120308517A1
(en)
|
2010-02-09 |
2012-12-06 |
Digna Biotech, S.L. |
Compositions for the treatment of infectious and tumoural diseases
|
|
HUE043894T2
(hu)
|
2011-06-10 |
2019-09-30 |
Bioverativ Therapeutics Inc |
Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
|
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
ES2529143B1
(es)
|
2011-10-21 |
2015-10-26 |
Abbvie Inc. |
Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc
|
|
CH707030B1
(de)
|
2011-10-21 |
2015-03-13 |
Abbvie Inc |
Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
|
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
|
EP2790506A4
(en)
*
|
2011-12-16 |
2015-02-11 |
David Gladstone Inst |
COMPOSITIONS AND METHODS FOR INHIBITING IMMUNE WEAK VIRUS TRANSCRIPTION
|
|
CN104271150A
(zh)
|
2012-01-12 |
2015-01-07 |
比奥根艾迪克Ma公司 |
嵌合因子viii多肽及其用途
|
|
NZ628014A
(en)
|
2012-02-15 |
2016-09-30 |
Biogen Ma Inc |
Recombinant factor viii proteins
|
|
MX369862B
(es)
|
2012-02-15 |
2019-11-25 |
Bioverativ Therapeutics Inc |
Composiciones del factor viii y metodos para hacerlas y usarlas.
|
|
CA2875247A1
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Chimeric clotting factors
|
|
AU2013270682A1
(en)
|
2012-06-08 |
2014-12-11 |
Biogen Ma Inc. |
Procoagulant compounds
|
|
RS59876B1
(sr)
|
2012-07-11 |
2020-03-31 |
Bioverativ Therapeutics Inc |
Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena
|
|
KR101520383B1
(ko)
|
2012-08-02 |
2015-05-15 |
에이비온 주식회사 |
Ｈｐｖ 감염과 관련된 암의 치료용 조성물
|
|
KR101363576B1
(ko)
*
|
2012-08-07 |
2014-02-24 |
가천대학교 산학협력단 |
알츠하이머 질환에 대한 신규 바이오마커 및 그의 용도
|
|
KR101363575B1
(ko)
*
|
2012-08-07 |
2014-02-24 |
가천대학교 산학협력단 |
신부전증에 대한 신규 바이오마커 및 그의 용도
|
|
WO2014036520A1
(en)
|
2012-08-30 |
2014-03-06 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
EP2908847B1
(en)
|
2012-10-18 |
2022-03-30 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
|
ES2959747T3
(es)
|
2013-02-15 |
2024-02-28 |
Bioverativ Therapeutics Inc |
Gen del factor VIII optimizado
|
|
UY35463A
(es)
|
2013-03-15 |
2014-10-31 |
Biogen Idec Inc |
Formulaciones de polipéptido fc-factor ix.
|
|
KR102714760B1
(ko)
|
2013-06-28 |
2024-10-11 |
바이오버라티브 테라퓨틱스 인크. |
Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
|
|
EP3033097B1
(en)
|
2013-08-14 |
2021-03-10 |
Bioverativ Therapeutics Inc. |
Factor viii-xten fusions and uses thereof
|
|
EP3048899B1
(en)
|
2013-09-25 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
On-column viral inactivation methods
|
|
EP3065769A4
(en)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Procoagulant fusion compound
|
|
PT4176894T
(pt)
|
2014-01-10 |
2024-05-21 |
Bioverativ Therapeutics Inc |
Proteínas quiméricas de fator viii e utilizações destas
|
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
|
EA201700181A1
(ru)
|
2014-10-14 |
2017-09-29 |
Галозим, Инк. |
Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
|
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
|
CA2994547A1
(en)
|
2015-08-03 |
2017-02-09 |
Bioverativ Therapeutics Inc. |
Factor ix fusion proteins and methods of making and using same
|
|
RU2614141C1
(ru)
*
|
2015-12-28 |
2017-03-23 |
федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) |
Способ прогнозирования парафарингиального абсцесса при остром паратонзиллите
|
|
EP3411478B1
(en)
|
2016-02-01 |
2022-06-08 |
Bioverativ Therapeutics Inc. |
Optimized factor viii genes
|
|
EP3448392A4
(en)
|
2016-04-28 |
2020-01-15 |
Emory University |
ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS
|
|
WO2018102743A1
(en)
|
2016-12-02 |
2018-06-07 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|
|
US12257288B2
(en)
|
2016-12-02 |
2025-03-25 |
Bioverativ Therapeutics Inc. |
Methods of inducing immune tolerance to clotting factors
|
|
EP3562840A1
(en)
|
2016-12-16 |
2019-11-06 |
Biogen MA Inc. |
Stabilized proteolytically activated growth differentiation factor 11
|
|
CA3051862A1
(en)
|
2017-01-31 |
2018-08-09 |
Bioverativ Therapeutics Inc. |
Factor ix fusion proteins and methods of making and using same
|
|
US10767164B2
(en)
|
2017-03-30 |
2020-09-08 |
The Research Foundation For The State University Of New York |
Microenvironments for self-assembly of islet organoids from stem cells differentiation
|
|
MY203184A
(en)
|
2017-08-09 |
2024-06-13 |
Bioverativ Therapeutics Inc |
Nucleic acid molecules and uses thereof
|
|
EP3746136A1
(en)
|
2018-02-01 |
2020-12-09 |
Bioverativ Therapeutics Inc. |
Use of lentiviral vectors expressing factor viii
|
|
JP7460609B2
(ja)
|
2018-05-14 |
2024-04-02 |
ウェアウルフ セラピューティクス， インコーポレイテッド |
活性化可能なインターロイキン－２ポリペプチド及びその使用方法
|
|
SG11202011308VA
(en)
|
2018-05-14 |
2020-12-30 |
Werewolf Therapeutics Inc |
Activatable cytokine polypeptides and methods of use thereof
|
|
SG11202010767SA
(en)
|
2018-05-18 |
2020-11-27 |
Bioverativ Therapeutics Inc |
Methods of treating hemophilia a
|
|
US12226451B2
(en)
|
2018-07-03 |
2025-02-18 |
Bristol-Myers Squibb Company |
FGF-21 formulations
|
|
MX2021001599A
(es)
|
2018-08-09 |
2021-07-02 |
Bioverativ Therapeutics Inc |
Moleculas de acido nucleico y sus usos para la terapia genica no viral.
|
|
WO2020118069A2
(en)
|
2018-12-06 |
2020-06-11 |
Bioverativ Therapeutics Inc. |
Use of lentiviral vectors expressing factor ix
|
|
EP3930687A4
(en)
|
2019-02-25 |
2023-06-07 |
The University of Chicago |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
|
|
EP3969035A4
(en)
|
2019-05-14 |
2023-06-21 |
Werewolf Therapeutics, Inc. |
SEPARATION UNITS AND METHODS AND THEIR USE
|
|
US12403164B2
(en)
|
2019-09-30 |
2025-09-02 |
Bioverativ Therapeutics Inc. |
Lentiviral vector formulations
|
|
MX2022005666A
(es)
|
2019-11-14 |
2022-10-07 |
Werewolf Therapeutics Inc |
Polipeptidos de citocina activables y metodos de uso de los mismos.
|
|
US20250288542A1
(en)
*
|
2020-10-01 |
2025-09-18 |
The Regents Of The University Of California |
Methods and compositions to treat and prevent viral infections and acute respiratory distress syndrome
|
|
WO2024080306A1
(ja)
*
|
2022-10-11 |
2024-04-18 |
Ｊｃｒファーマ株式会社 |
血清アルブミンと生理活性を有する蛋白質との融合蛋白質
|